ly900003
Nucleic acidexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started May 1, 1998 (NCT00003236)
Timeline
Indications
Mechanism of action
- Protein kinase C alphaINHIBITOR
PRKCA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- cgp64128a
- cgp 64128a
- isi641a
- isi 641a
- isi-641a
- isis 3521
- isis 3521
- isis 3521
- ly900003
- ly900003
- ly900003
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00042679 | Phase 2 | Jun 1, 2002 | Eli Lilly |
| NCT00034268 | Phase 3 | Mar 1, 2002 | Eli Lilly |
| NCT00017407 | Phase 3 | Oct 1, 2000 | Ionis Pharmaceuticals, Inc. |
| NCT00003989 | Phase 2 | Jun 1, 1998 | European Organisation for Research and Treatment of Cancer, University of Basel |
| NCT00003236 | Phase 2 | May 1, 1998 | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), Northwestern University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 2 | 2 | 2 | 2002 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 1 | 1 | 1 | 1998 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 1998 |
| Ionis Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2000 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1998 |
| Northwestern University | Academic/Hospital | 1 | 0 | 1 | 1998 |
| University of Basel | Academic/Hospital | 1 | 0 | 1 | 1998 |
7 organizations
Page 1 / 1